The clinical development of MEK inhibitors

Nature Reviews Clinical Oncology

Volumn 11, Issue 7, 2014, Pages 385-400

  Zhao, Yujie ^a   Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; ANTINEOPLASTIC AGENT; AZD 8330; BAY 86 9766; BINIMETINIB; BIOLOGICAL MARKER; CH 5126766; COBIMETINIB; CYTOTOXIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MSC 1936369B; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; RAF PROTEIN; RAS PROTEIN; RDEA 119; REFAMETINIB; RG 7421; RO 5126766; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; CREATINE KINASE; GDC 0623; PDO 325901; TAK 733; TRIACYLGLYCEROL LIPASE; WX 554;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; EYE TOXICITY; FATIGUE; HUMAN; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT; ACNE; CENTRAL SEROUS RETINOPATHY; CONFUSION; DEHYDRATION; DISEASE ASSOCIATION; DIZZINESS; DRUG APPROVAL; DRUG PROTEIN BINDING; DRUG SAFETY; FAINTNESS; HYPOXIA; MACULAR EDEMA; PHARYNGITIS; PRESYNCOPE; PUSTULE; RETINA DETACHMENT; RETINOPATHY; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSTEADY GAIT; VISUAL DISORDER;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84903537320     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.83     Document Type: Review

References (209)

1. Robinson, M. J. & Cobb, M. H. Mitogen-Activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186 (1997).
2. Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37-40 (2001).
3. Cowley, S., Paterson, H., Kemp, P. & Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852 (1994).
4. Pandey, S. K., Theberge, J. F., Bernier, M. & Srivastava, A. K. Phosphatidylinositol 3 kinase requirement in activation of the Ras/C raf 1/MEK/ERK and p70(S6K) signaling cascade by the insulinomimetic agent vanadyl sulfate. Biochemistry 38, 14667-14675 (1999).
5. Marais, R. et al. Requirement of Ras GTP-Raf complexes for activation of Raf 1 by protein kinase C. Science 280, 109-112 (1998).
6. Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414 (1994).
7. Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf 1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136-3145 (1995).
8. Kolch, W., Heidecker, G., Lloyd, P. & Rapp, U. R. Raf 1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349, 426-428 (1991).
9. Fischmann, T. O. et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48, 2661-2674 (2009).
10. Liang, H., Liu, T., Chen, F., Liu, Z. & Liu, S. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Sci. China Life Sci. 54, 336-341 (2011).
11. Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197 (2004).
12. Trujillo, J. I. MEK inhibitors: A patent review 2008-2010. Expert Opin. Ther. Pat. 21, 1045-1069 (2011).
13. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457-2467 (2012).
14. Xing, M. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clin. Endocrinol. (Oxford) 63, 263-266 (2005).
15. Sieben, N. L. et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202, 336-340 (2004).
16. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002).
17. Friday, B. B. & Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-Activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14, 342-346 (2008).
18. COSMIC catalogue of somatic mutations in cancer. COSMIC gene overview: BRAF [online], http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=BRAF (2014).
19. Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G protein coupled receptors. Nature 379, 557-560 (1996).
20. Hou, P., Liu, D. & Xing, M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr. Relat. Cancer 18, 687-697 (2011).
21. Roskoski, R. Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res. 66, 105-143 (2012).
22. Meloche, S. & Pouyssegur, J. The ERK1/2 mitogen-Activated protein kinase pathway as a master regulator of the G1-To S phase transition. Oncogene 26, 3227-3239 (2007).
23. Shaul, Y. D. & Seger, R. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim. Biophys. Acta 1773, 1213-1226 (2007).
24. Lewis, T. S., Shapiro, P. S. & Ahn, N. G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139 (1998).vev
25. Alberola-Ila, J., Forbush, K. A., Seger, R., Krebs, E. G. & Perlmutter, R. M. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 373, 620-623 (1995).
26. Johnson, G. L. & Vaillancourt, R. R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell Biol. 6, 230-238 (1994).
27. D'Angelo, G., Struman, I., Martial, J. & Weiner, R. I. Activation of mitogen-Activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N terminal fragment of prolactin. Proc. Natl Acad. Sci. USA 92, 6374-6378 (1995).
28. Na, J., Furue, M. K. & Andrews, P. W. Inhibition of ERK1/2 prevents neural and mesendodermal differentiation and promotes human embryonic stem cell self-renewal. Stem Cell Res. 5, 157-169 (2010).
29. Raman, M., Chen, W. & Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene 26, 3100-3112 (2007).
30. Repasky, G. A., Chenette, E. J. & Der, C. J. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14, 639-647 (2004).
31. Scita, G. et al. Signaling from Ras to Rac and beyond: Not just a matter of GEFs. EMBO J. 19, 2393-2398 (2000).
32. Castellano, E. & Downward, J. RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2, 261-274 (2011).
33. Hamad, N. M. et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057 (2002).
34. LoRusso, P. M. et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI 1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281-5293 (2005).
35. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
36. US Food and Drug Administration. NDA 204114 approval [online], http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2013/204114Orig1s000ltr. pdf (2013).
37. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
38. Wang, S., Ghosh, R. N. & Chellappan, S. P. Raf 1 physically interacts with Rb and regulates its function: A link between mitogenic signaling and cell cycle regulation. Mol. Cell Biol. 18, 7487-7498 (1998).
39. Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf 1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783-7788 (2001).
40. O'Neill, E., Rushworth, L., Baccarini, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf 1. Science 306, 2267-2270 (2004).
41. Piazzolla, D., Meissl, K., Kucerova, L., Rubiolo, C. & Baccarini, M. Raf 1 sets the threshold of Fas sensitivity by modulating Rok-α signaling. J. Cell Biol. 171, 1013-1022 (2005).
42. Matallanas, D. et al. Raf family kinases: Old dogs have learned new tricks. Genes Cancer 2, 232-260 (2011).
43. Rauch, J. et al. Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A Raf transcription. Cancer Res. 70, 1679-1688 (2010).
44. Castellano, E. & Downward, J. Role of RAS in the regulation of PI 3-kinase. Curr. Top. Microbiol. Immunol. 346, 143-169 (2010).
45. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf 1/B-Raf heterodimerization. Mol. Cell Biol. 26, 2262-2272 (2006).
46. Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B Raf signaling. Mol. Cell Biol. 30, 806-819 (2010).
47. Brummer, T., Naegele, H., Reth, M. & Misawa, Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C terminus of B Raf. Oncogene 22, 8823-8834 (2003).
48. Dougherty, M. K. et al. Regulation of Raf 1 by direct feedback phosphorylation. Mol. Cell 17, 215-224 (2005).
49. Friday, B. B. et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 6145-6153 (2008).
50. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
51. Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-Arm, phase 2 study. Lancet Oncol. 14, 134-140 (2013).
52. Bekaii-Saab, T. et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol. 29, 2357-2363 (2011).
53. Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623-632 (2013).
54. Janne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non small cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013).
55. Shapiro, G. et al. Clinical combination of the MEK inhibitor GDC 0973 and the PI3K inhibitor GDC 0941: A first in human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 29 (Suppl.), a3005 (2011).
56. LoRusso, P. M. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD 0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937 (2010).
57. Falchook, G. S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789 (2012).
58. Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L. & Bedard, P. L. Ocular toxicity of targeted therapies. J. Clin. Oncol. 30, 3277-3286 (2012).
59. Chen, X., Schwartz, G. K., DeAngelis, L. M., Kaley, T. & Carvajal, R. D. Dropped head syndrome: Report of three cases during treatment with a MEK inhibitor. Neurology 79, 1929-1931 (2012).
60. Cohen, R. B. et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur. J. Cancer 49, 1521-1529 (2013).
61. Borad, M. J. et al. Phase I dose-escalation study of E6201, a MEK 1 inhibitor, in advanced solid tumors [abstract]. J. Clin. Oncol. 28 (Suppl.), a2505 (2010).
62. Sequist, L. V. et al. First in human evaluation of CO 1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M [abstract]. J. Clin. Oncol. 31 (Suppl.), a2524 (2013).
63. Mehra, R. et al. First in human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3007 (2012).
64. Camidge, D. R. et al. First in human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results [abstract]. J. Clin. Oncol. 31 (Suppl.), a8031 (2013).
65. Harding, J. J. et al. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9060 (2013).
66. Long, G. V. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095 (2012).
67. Barrett, S. D. et al. The discovery of the benzhydroxamate MEK inhibitors CI 1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18, 6501-6504 (2008).
68. Sebolt-Leopold, J. S. et al. The biological profile of PD 0325901: A second generation analog of CI 1040 with improved pharmaceutical potential [abstract]. Proc. Amer. Assoc. Cancer Res. 45, a4003 (2004).
69. Huang, W. et al. PD0325901, a mitogen-Activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J. Ocul. Pharmacol. Ther. 25, 519-530 (2009).
70. Haura, E. B. et al. A phase II study of PD 0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450-2457 (2010).
71. Britten, C. et al. Multi-Arm phase 1 dose escalation study of safety, pharmacokinetics, and pharmacodynamics of the dual PI3K/mTOR inhibitors PF 04691502 (oral) and PF 05212384 (IV) in combination with the MEK inhibitor PD 0325901 or irinotecan in patients with advanced cancer. Eur. J. Cancer 48, 109 (2012).
72. Yeh, T. C. et al. Biological characterization of ARRY 142886 (AZD6244), a potent, highly selective mitogen-Activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583 (2007).
73. Haass, N. K. et al. The mitogen-Activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY 142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 14, 230-239 (2008).
74. Davies, B. R. et al. AZD6244 (ARRY 142886), a potent inhibitor of mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219 (2007).
75. Huynh, H., Soo, K. C., Chow, P. K. & Tran, E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY 142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther. 6, 138-146 (2007).
76. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY 142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008).
77. Banerji, U. et al. The first in human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY 142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 16, 1613-1623 (2010).
78. Catalanotti, F. et al. Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K-mutated melanoma. Clin. Cancer Res. 19, 2257-2264 (2013).
79. Hayes, D. N. et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY 142886) in iodine 131 refractory papillary thyroid carcinoma with or without follicular elements. Clin. Cancer Res. 18, 2056-2065 (2012).
80. O'Neil, B. H. et al. Phase II study of the mitogen-Activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 29, 2350-2356 (2011).
81. Jain, N, C. et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) [abstract]. J. Clin. Oncol. 30 (Suppl.), a6582 (2012).
82. Khan, K. H. et al. A phase I dose escalation study of oral MK 2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY 142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 28, e13599 (2012).
83. Kirkwood, J. M. et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567 (2012).
84. Hainsworth, J. D. et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY 142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J. Thorac. Oncol. 5, 1630-1636 (2010).
85. Bodoky, G. et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY 142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 30, 1216-1223 (2012).
86. Bennouna, J. et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY 142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest. New Drugs 29, 1021-1028 (2011).
87. Robert, C. et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study. Lancet Oncol. 14, 733-740 (2013).
88. Deming, D. A. et al. A phase I study of selumetinib (AZD6244/ARRY 142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a3103 (2012).
89. Durante, C. et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92, 2840-2843 (2007).
90. Knauf, J. A., Kuroda, H., Basu, S. & Fagin, J. A. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-Ras-MAP kinase. Oncogene 22, 4406-4412 (2003).
91. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01586624?term= selumetinib+with+vandetanib&rank=1 (2013).
92. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01061749?term= cixutumumab+and+selumetinib&rank=1 (2013).
93. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01116271?term= irinotecan+and+Selumetinib&rank=1 (2013).
94. Hochster, H. S. et al. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY 142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3587 (2013).
95. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01949870?term= gemcitabine+and+selumetinib&rank=3 (2014).
96. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01949870?term=NCT01949870&rank=1 (2014).
97. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01809210?term=NCT01809210&rank=1 (2014).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01783197?term=NCT01783197&rank=1 (2014).
99. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01146756?term=NCT01146756&rank=1 (2014).
100. Gupta, A. et al. DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY 142886) in wt BRAF advanced melanoma [abstract]. J. Clin. Oncol. 31 (Suppl.), a9068 (2013).
101. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01229150?term=NCT01229150&rank=1 (2014).
102. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01222689?term=NCT01222689&rank=1 (2014).
103. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01206140?term=NCT01206140&rank=1 (2014).
104. Rice, K. D. et al. Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC 0973). ACS Med. Chem. Lett. 3, 416-421 (2012).
105. Fremin, C. & Meloche, S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 3, 8 (2010).
106. Rosen, L. S. et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a14585 (2008).
107. LoRusso, P. et al. A first in human phase Ib study to evaluate the MEK inhibitor GDC 0973, combined with the pan-PI3K inhibitor GDC 0941, in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a2566 (2012).
108. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
109. Nazarian, R. et al. Melanomas acquire resistance to B RAF(V600E) inhibition by RTK or N RAS upregulation. Nature 468, 973-977 (2010).
110. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
111. Gonzalez, R et al. Phase ib study of vemurafenib in combination with the MEK inhibitor, GDC 0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7) [abstract 2744]. Presented at the 37th ESMO congress 2012.
112. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01689519?term=cobimetinib+vemurafenib& rank=1 (2014).
113. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01562275?term=GDC 0068+cobimetinib& rank=1 (2014).
114. Iverson, C. et al. RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69, 6839-6847 (2009).
115. Weekes, C. D. et al. Multicenter phase i trial of the mitogen-Activated protein kinase 1/2 inhibitor BAY 86 9766 in patients with advanced cancer. Clin. Cancer Res. 19, 1232-1243 (2013).
116. Schmieder, R. et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86 9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161-1171 (2013).
117. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01915602?term=refametinib+sorafenib& rank=1 (2014).
118. Whittaker, S., Marais, R. & Zhu, A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010).
119. Lim, H. Y. et al. A phase II trial of MEK inhibitor BAY 86 9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a4103 (2012).
120. Van Laethem, J. L. et al. A phase I/II study of the MEK inhibitor BAY 86 9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results [abstract]. J. Clin. Oncol. 30 (Suppl.), a4050 (2012).
121. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01392521?term=NCT01392521&rank=1 (2014).
122. Gilmartin, A. G. et al. GSK1120212 (JTP 74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
123. Infante, J. R. et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol. 13, 773-781 (2012).
124. US Food and Drug Administration. Vemurafenib [online], http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm268301.htm (2011).
125. Eggermont, A. M. & Robert, C. New drugs in melanoma: It's a whole new world. Eur. J. Cancer 47, 2150-2157 (2011).
126. US Food and Drug Administration. Dabrafenib [online], http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm354477.htm (2013).
127. Kim, K. B. et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489 (2013).
128. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01979523?term=GSK2141795+Trametinib& rank=6 (2013).
129. US Food and Drug Administration. Trametinib and Dabrafenib [online], http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htm (2014).
130. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01584648?term=NCT01584648&rank=1 (2014).
131. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01682083?term=COMBI-AD&rank=1 (2014).
132. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01597908?term=COMBI v&rank=1 (2014).
133. Infante, J. R. et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [abstract]. J. Clin. Oncol. 30 (Suppl.), a291 (2013).
134. Becerra, C. et al. A five-Arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3023 (2012).
135. Ahmed, S. R. et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), TPS3117 (2012).
136. Infante, J. R. et al. A phase Ib study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results [abstract]. Mol. Cancer Ther. 10 (Suppl. 1), B128 (2011).
137. Kurzrock, R. et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795) [abstract]. J. Clin. Oncol. 29 (Suppl.), a3085 (2011).
138. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01938443?term=GSK2256098+trametinib& rank=1 (2014).
139. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02079740?term=navitoclax+trametinib& rank=2 (2014).
140. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01740648?term=5- fluorouracil++trametinib&rank=1 (2013).
141. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01155453?term=BKM120+trametinib&rank= 1 (2013).
142. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01723202?term=Trametinib+dabrafenib& rank=8 (2014).
143. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01336634?term=Trametinib+dabrafenib& rank=11 (2014).
144. Kim, K. et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 149, 537-549 (2010).
145. Delord, J. et al. First in human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 28 (Suppl.), a2504 (2010).
146. Houede, N. et al. Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies [abstract]. J. Clin. Oncol. 29 (Suppl.), a3019 (2011).
147. Macarulla, T. et al. Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369B) as second-line treatment for KRAS mutated metastatic colorectal cancer. Ann. Oncol. 23 iv19-iv30 (2012).
148. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01936363?term=pimasertib+SAR245409& rank=1 (2014).
149. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01390818?term=pimasertib+SAR245409& rank=2 (2013).
150. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01378377?term=pimasertib+temsirolimus& rank=1 (2013).
151. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01693068?term=pimasertib+dacarbazine& rank=1 (2013).
152. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01016483?term=pimasertib+gemcitabine& rank=1 (2013).
153. Bendell, J. C. et al. A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY 438162) in patients with advanced solid tumors [abstract]. Mol. Cancer Ther. 10 (Suppl. 1), B243 (2011).
154. Richard, S. et al. A phase I study of MEK inhibitor MEK162 (ARRY 438162) in patients with biliary tract cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), a220 (2012).
155. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01828034?term= gemcitabine+and+cisplatin+MEK162&rank=1 (2014).
156. Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256 (2013).
157. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01320085?term=MEK162+NRAS&rank=1 (2014).
158. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01763164?term=MEK162+NRAS&rank=3 (2014).
159. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01801358?term=MEK162+AEB071&rank=1 (2013).
160. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01781572?term=MEK162+LEE011&rank=1 (2014).
161. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01562899?term=AMG479+MEK162&rank=1 (2014).
162. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01909453?term=LGX818+MEK162&rank=1 (2013).
163. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01352273?term=RAF265+MEK162&rank=1 (2013).
164. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01449058?term=MEK162+BYL719&rank=1 (2013).
165. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01820364?term=MEK162+BKM120&rank=2 (2013).
166. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01363232?term=MEK162+BKM120&rank=1 (2013).
167. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01337765?term=BEZ235+MEK162&rank=1 (2013).
168. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01649336?term=paclitaxel+MEK162&rank=1 (2013).
169. Wallace, E et al. AZD8330 (ARRY 424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials [abstract 3696]. Presented at the AACR 100th Annual Meeting 2009.
170. Lee, L. et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: Target suppression using a biomarker. Clin. Cancer Res. 15, 7368-7374 (2009).
171. Leijen, S. et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin. Cancer Res. 18, 4794-4805 (2012).
172. Ishii, N. et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060 (2013).
173. Martinez-Garcia, M. et al. First in human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first in class dual MEK/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 18, 4806-4819 (2012).
174. Mala, C. et al. A phase I, first in human single ascending dose study of the MEK inhibitor WX 554 given to healthy male subjects [abstract]. J. Clin. Oncol. 28 (Suppl.), e13666 (2010).
175. Sosman, J. A. et al. First in human, multicenter, dose-escalation, phase I study of the investigational drug TAK 733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS145 (2011).
176. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01859351?term=WX 554&rank=2 (2013).
177. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01581060?term=WX 554&rank=1 (2012).
178. El-Khoueiry, A. et al. A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC 0623 in patients with advanced solid tumors [abstract]. Mol. Cancer Ther. 12, B75 (2013).
179. Adjei, A. A. et al. Phase I, dose-escalation study of the investigational drug TAK 733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2528 (2013).
180. Hatzivassiliou, G. et al. RAF inhibitors prime wild type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
181. Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 501, 232-236 (2013).
182. Jing, J. et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol. Cancer Ther. 11, 720-729 (2012).
183. Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273 (2010).
184. Gore, L. et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86 9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), a3007 (2011).
185. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01933932?term=NCT01933932&rank=1 (2014).
186. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01143402?term=NCT01143402&rank=1 (2013).
187. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01750281?term=NCT01750281&rank=1 (2014).
188. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01843062?term=NCT01843062&rank=1 (2014).
189. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01658943?term=NCT01658943&rank=1 (2013).
190. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01160718?term=NCT01160718&rank=1 (2013).
191. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01278615?term=NCT01278615&rank=1 (2014).
192. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT00888134?term=NCT00888134&rank=1 (2014).
193. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01089101?term=NCT01089101&rank=1 (2013).
194. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01752569?term=NCT01752569&rank=1 (2012).
195. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01519427?term=NCT01519427&rank=1 (2013).
196. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01362296?term=NCT01362296&rank=1 (2013).
197. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT02042443?term=NCT02042443&rank=1 (2014).
198. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01935973?term=NCT01935973&rank=1 (2014).
199. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01990196?term=NCT01990196&rank=1 (2014).
200. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01943864?term=NCT01943864&rank=1 (2014).
201. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01726738?term=NCT01726738&rank=1 (2013).
202. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01941927?term=NCT01941927&rank=1 (2013).
203. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01907815?term=NCT01907815&rank=1 (2013).
204. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01750918?term=NCT01750918&rank=1 (2014).
205. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01701037?term=NCT01701037&rank=1 (2013).
206. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01619774?term=NCT01619774&rank=1 (2014).
207. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01915589?term=NCT01915589&rank=1 (2014).
208. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01849874?term=NCT01849874&rank=1 (2014).
209. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrial.gov/ct2/show/NCT01927341?term=NCT01927341&rank=1 (2014).